Determination of Regulatory Review Period for Purposes of Patent Extension; Fotivda

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for patent extension of the human drug product Fotivda, as required by law, following submissions to the U.S. Patent and Trademark Office (USPTO).